Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Research Highlights Potential And Pitfalls Of BRAF Inhibitors

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Surprisingly positive data from two early-stage trials in metastatic melanoma with Plexxikon/Roche’s BRAF inhibitor, PLX-4032, and its quick move into Phase III, is garnering attention for the new class of cancer therapy. But there is one troubling sign of toxicity, and other research on the BRAF pathway is prompting debate over the pros and cons of specific versus broad activity.

You may also be interested in...



Deciphera Readies For Next Steps; Brings Third Compound Into Phase I

The newly relocated biotech is shifting its focus from science to business development as it moves its third compound into the clinic and begins looking for partners for its other programs.

Plexxikon, Roche Near Catalyst For BRAF Inhibitor In Melanoma

As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.

Array Biopharma Wins Two Important Deals In Six Months, But Wall Street Shrugs

To management's frustration, the biotech's deals with Novartis and Amgen haven't helped its market cap, one more sign that validating deals with Big Pharma don't move investors.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel